AbbVie Inc.
AbbVie Reports Strong Q2 2026 Financial Results and Announces Acquisition of Apogee Therapeutics
Summary
AbbVie Inc. reported strong second-quarter 2026 financial results, with worldwide net revenues of $16.990 billion, an increase of 10.2 percent on a reported basis. Diluted EPS on a GAAP basis was $2.03, and adjusted diluted EPS was $3.65. The company also announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, which is expected to close in Q3 2026. AbbVie updated its 2026 adjusted diluted EPS guidance range to $13.87 - $14.07, reflecting a $0.14 per share dilutive impact from the proposed acquisition. Additionally, AbbVie received several regulatory approvals for its products, including Skyrizi, Rinvoq, and Decnupaz.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement